Viking Therapeutics, Inc. Total Assets

• Viking Therapeutics, Inc. showed a decrease of -21.2% in Total Assets from 2024 to 2025.
• This data is from Viking Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 11, 2026.
• XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2015: $2.77 million | Q2 2015: $22.27 million | Q3 2015: $19.01 million | Q1 2016: $12.76 million | Q2 2016: $18.55 million | Q3 2016: $16.32 million | Q1 2017: $15.15 million | Q2 2017: $14.32 million | Q3 2017: $11.84 million | Q1 2018: $78.97 million | Q2 2018: $144.47 million | Q3 2018: $306.80 million | Q1 2019: $300.08 million | Q2 2019: $294.49 million | Q3 2019: $290.12 million | Q1 2020: $277.10 million | Q2 2020: $271.20 million | Q3 2020: $263.62 million | Q1 2021: $250.14 million | Q2 2021: $237.85 million | Q3 2021: $224.47 million | Q1 2022: $195.03 million | Q2 2022: $181.51 million | Q3 2022: $166.68 million | Q1 2023: $150.90 million | Q2 2023: $400.69 million | Q3 2023: $382.66 million | Q1 2024: $967.52 million | Q2 2024: $946.84 million | Q3 2024: $937.89 million | Q1 2025: $866.99 million | Q2 2025: $827.85 million | Q3 2025: $739.42 million.
• Over the full 12 years of available data (2014 to 2025), Viking Therapeutics, Inc.'s Total Assets has grown by 23,419.5%.
• Historical annual values: Fiscal year 2025: $715.73 million | Fiscal year 2024: $908.32 million | Fiscal year 2023: $368.49 million | Fiscal year 2022: $168.53 million | Fiscal year 2021: $210.66 million | Fiscal year 2020: $256.50 million | Fiscal year 2019: $284.26 million | Fiscal year 2018: $302.31 million | Fiscal year 2017: $22.12 million | Fiscal year 2016: $14.54 million | Fiscal year 2015: $15.44 million | Fiscal year 2014: $3.04 million.
• Data sourced from SEC EDGAR public filings as of August 7, 2026.

Last verified: August 7, 2026